BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferrari SM, Centanni M, Virili C, Miccoli M, Ferrari P, Ruffilli I, Ragusa F, Antonelli A, Fallahi P. Sunitinib in the Treatment of Thyroid Cancer. Curr Med Chem 2019;26:963-72. [PMID: 28990511 DOI: 10.2174/0929867324666171006165942] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu W, Ye C, Qing X, Liu S, Lv X, Wang W, Dong X, Zhang Y. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Mater Today Bio 2022;16:100358. [PMID: 35880099 DOI: 10.1016/j.mtbio.2022.100358] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Liu C, Liu D, Wang F, Liu Y, Xie J, Xie J, Xie Y. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1038927] [Reference Citation Analysis]
3 Li J, Shi M, Chen Z, Pan Y. DeepPurpose-based drug discovery in chondrosarcoma. Chinese Journal of Plastic and Reconstructive Surgery 2022. [DOI: 10.1016/j.cjprs.2022.10.004] [Reference Citation Analysis]
4 ElHady AK, El-Gamil DS, Abadi AH, Abdel-Halim M, Engel M. An overview of cdc2-like kinase 1 (Clk1) inhibitors and their therapeutic indications. Med Res Rev 2022. [PMID: 36262046 DOI: 10.1002/med.21928] [Reference Citation Analysis]
5 Chen H, Zhang J, Sun X, Wang Y, Qian Y. Mitophagy-mediated molecular subtypes depict the hallmarks of the tumour metabolism and guide precision chemotherapy in pancreatic adenocarcinoma. Front Cell Dev Biol 2022;10:901207. [DOI: 10.3389/fcell.2022.901207] [Reference Citation Analysis]
6 Ragusa F, Ferrari SM, Elia G, Paparo SR, Balestri E, Botrini C, Patrizio A, Mazzi V, Guglielmi G, Foddis R, Spinelli C, Ulisse S, Antonelli A, Fallahi P. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. Int J Mol Sci 2022;23:5731. [PMID: 35628540 DOI: 10.3390/ijms23105731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Xiang C, Sun WH, Ke Y, Yu X, Wang Y. CDCA8 Contributes to the Development and Progression of Thyroid Cancer through Regulating CDK1. J Cancer 2022;13:2322-35. [PMID: 35517403 DOI: 10.7150/jca.64747] [Reference Citation Analysis]
8 Sobocki BK, Perdyan A, Szot O, Rutkowski J. Management of Pheochromocytomas and Paragangliomas: A Case-Based Review of Clinical Aspects and Perspectives. J Clin Med 2022;11:2591. [PMID: 35566714 DOI: 10.3390/jcm11092591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, Guo SD. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. Int J Biol Macromol 2022;202:539-57. [PMID: 35074329 DOI: 10.1016/j.ijbiomac.2022.01.113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
10 Lu S, Hong Y, Chen H, Wu L, Sun F, Wang J, Zhu J, Que Y, Zhang L, Zhen Z, Sun X, Huang J, Zhang Y. The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors. Front Pharmacol 2022;13:711704. [DOI: 10.3389/fphar.2022.711704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ma Y, Liu X, Bi Y, Wang T, Chen C, Wang Y, Han D, Cao F. Alteration of N6-Methyladenosine mRNA Methylation in a Human Stem Cell-Derived Cardiomyocyte Model of Tyrosine Kinase Inhibitor-Induced Cardiotoxicity. Front Cardiovasc Med 2022;9:849175. [DOI: 10.3389/fcvm.2022.849175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Tarasi F, Lanza PA, Ferretti V, Echeverría GA, Piro OE, Cacicedo M, Gehring S, León IE, Islas MS. Synthesis and Characterization of Novel Copper(II)-Sunitinib Complex: Molecular Docking, DFT Studies, Hirshfeld Analysis and Cytotoxicity Studies. Inorganics 2022;10:3. [DOI: 10.3390/inorganics10010003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mishra P, Laha D, Grant R, Nilubol N. Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer. Cancers (Basel) 2021;13:6194. [PMID: 34944814 DOI: 10.3390/cancers13246194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hu J, Xing K, Zhang Y, Liu M, Wang Z. Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study (Preprint).. [DOI: 10.2196/preprints.34548] [Reference Citation Analysis]
15 Hu J, Xing K, Zhang Y, Liu M, Wang Z. Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study (Preprint). JMIR Medical Informatics. [DOI: 10.2196/34548] [Reference Citation Analysis]
16 Mou L, Tian X, Zhou B, Zhan Y, Chen J, Lu Y, Deng J, Deng Y, Wu Z, Li Q, Song Y, Zhang H, Chen J, Tian K, Ni Y, Pu Z. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Front Oncol 2021;11:752725. [PMID: 34707994 DOI: 10.3389/fonc.2021.752725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
17 Wei G, Shu X, Zhou Y, Liu X, Chen X, Qiu M. Intra-Abdominal Desmoplastic Small Round Cell Tumor: Current Treatment Options and Perspectives. Front Oncol 2021;11:705760. [PMID: 34604040 DOI: 10.3389/fonc.2021.705760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Mari G, Corrieri M, De Crescentini L, Favi G, Santeusanio S, Mantellini F. FeCl 3 ‐Catalyzed Formal [3+2] Cyclodimerization of 4‐Carbonyl‐1,2‐diaza‐1,3‐dienes. Eur J Org Chem 2021;2021:5202-8. [DOI: 10.1002/ejoc.202101046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, Miccoli M, Galdiero MR, Varricchi G, Foddis R, Guglielmi G, Spinelli C, La Motta C, Benvenga S, Antonelli A, Fallahi P. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. Expert Opin Investig Drugs 2021;30:913-21. [PMID: 34428101 DOI: 10.1080/13543784.2021.1972971] [Reference Citation Analysis]
20 Agrawal AK, Noronha V, Patil V, Menon N, Kapoor A, Chougule A, Chandrani P, Prabhash K. Systemic Therapy in Thyroid Cancer. Indian J Surg Oncol. [DOI: 10.1007/s13193-021-01398-2] [Reference Citation Analysis]
21 Huang Z, Su Q, Li W, Ren H, Huang H, Wang A. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma. J Genet Genomics 2021:S1673-8527(21)00201-0. [PMID: 34373220 DOI: 10.1016/j.jgg.2021.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Hyytiäinen A, Wahbi W, Väyrynen O, Saarilahti K, Karihtala P, Salo T, Al-Samadi A. Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? Front Oncol 2021;11:683570. [PMID: 34195084 DOI: 10.3389/fonc.2021.683570] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Carrera AN, Grant MKO, Zordoky BN. CYP1B1 as a therapeutic target in cardio-oncology. Clin Sci (Lond) 2020;134:2897-927. [PMID: 33185690 DOI: 10.1042/CS20200310] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
24 ElHady AK, El-Gamil DS, Chen PJ, Hwang TL, Abadi AH, Abdel-Halim M, Engel M. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency. Molecules 2021;26:1001. [PMID: 33668683 DOI: 10.3390/molecules26041001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol 2020:S1044-579X(20)30249-2. [PMID: 33249201 DOI: 10.1016/j.semcancer.2020.11.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
26 Chen L, Xu P, Xiao Q, Chen L, Li S, Jian JM, Zhong YB. Sunitinib malate inhibits intestinal tumor development in male ApcMin/+ mice by down-regulating inflammation-related factors with suppressing β-cateinin/c-Myc pathway and re-balancing Bcl-6 and Caspase-3. Int Immunopharmacol 2021;90:107128. [PMID: 33191180 DOI: 10.1016/j.intimp.2020.107128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Liu Y, Ma R, Wang Q, Si C, Wei B. Er(OTf)3-catalyzed approach to 3-alkenylindoles through regioselective addition of ynamides and indoles. Tetrahedron 2020;76:131649. [DOI: 10.1016/j.tet.2020.131649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhang L, Niu X, Bi Y, Cui H, Li H, Cheng X. Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma. Technol Cancer Res Treat 2020;19:1533033820948060. [PMID: 32924793 DOI: 10.1177/1533033820948060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Dzobo K, Senthebane DA, Ganz C, Thomford NE, Wonkam A, Dandara C. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells 2020;9:E1896. [PMID: 32823711 DOI: 10.3390/cells9081896] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 20.0] [Reference Citation Analysis]
30 San Román Gil M, Pozas J, Molina-Cerrillo J, Gómez J, Pian H, Pozas M, Carrato A, Grande E, Alonso-Gordoa T. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. Int J Mol Sci 2020;21:E4951. [PMID: 32668761 DOI: 10.3390/ijms21144951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
31 Fallahi P, Ferrari SM, Elia G, Ragusa F, Patrizio A, Paparo SR, Marone G, Galdiero MR, Guglielmi G, Foddis R, Cristaudo A, Antonelli A. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Semin Cancer Biol 2020:S1044-579X(20)30149-8. [PMID: 32569821 DOI: 10.1016/j.semcancer.2020.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Sheppard-Olivares S, Bello NM, Wood E, Szivek A, Biller B, Hocker S, Wouda RM. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018). Vet Comp Oncol 2020;18:519-27. [PMID: 32012432 DOI: 10.1111/vco.12571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
33 Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel treatments for anaplastic thyroid carcinoma. Gland Surg 2020;9:S28-42. [PMID: 32055496 DOI: 10.21037/gs.2019.10.18] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 16.5] [Reference Citation Analysis]
34 Ancker OV, Krüger M, Wehland M, Infanger M, Grimm D. Multikinase Inhibitor Treatment in Thyroid Cancer. Int J Mol Sci 2019;21:E10. [PMID: 31861373 DOI: 10.3390/ijms21010010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
35 Xu L, Li L, Zhang J, Cai W, Zhao S, Liu S. Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells. Odontology 2020;108:300-11. [PMID: 31529315 DOI: 10.1007/s10266-019-00451-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Biava PM, Nicolini A. New Insights into the Complexity of Cancer and of Inflammatory Diseases. Curr Med Chem 2019;26:940. [PMID: 31113340 DOI: 10.2174/092986732606190513093422] [Reference Citation Analysis]